Literature DB >> 19069150

[Assessment of competence of predialysis chronic kidney disease stage 5 patients to make treatment decisions: preliminary report].

Hiroyuki Terawaki1, Toshinobu Sato, Nobuyoshi Miura, Keiko Saito, Naoko Mifune, Wataru Shoji, Hironao Sato, Ayano Yokota, Akira Sugiura, Masashi Iwabuchi, Masahiro Miyata, Yaeko Murata, Keisuke Nakayama, Junpei Suzuki, Masaki Nakamura, Sadayoshi Ito, Masaaki Nakayama, Takashi Ueno.   

Abstract

The competence to consent to treatment of 26 adults with stage 5 predialysis chronic kidney disease (CKD) (16 males, 10 females, age; 58 +/- 11 years, creatinine clearance; 10.1 +/- 3.9 mL/min)was assessed using two kinds of format: the MacArthur Competence Assessment Tool-Treatment (MacCAT-T) and mini-mental-state examination (MMSE). The MacCAT-T revealed poor ability for understanding(3.72 +/- 1.11 points; perfect score, 6 points), appreciating (2.88 +/- 0.88 points; perfect score, 4 points)and reasoning(4.30 +/- 2.11 points; perfect score, 8 points). The MMSE revealed poor performance on the attentional task. The level of attentional deficit was significantly related to both poor ability for understanding and reasoning (r = 0.432, p = 0.031 and r = 0.542, p = 0.014, respectively). These results suggest that the competence of predialysis CKD stage 5 patients to consent to treatment is impaired partly via an attentional deficit.

Entities:  

Mesh:

Year:  2008        PMID: 19069150

Source DB:  PubMed          Journal:  Nihon Jinzo Gakkai Shi        ISSN: 0385-2385


  2 in total

1.  Cognitive function and advanced kidney disease: longitudinal trends and impact on decision-making.

Authors:  Osasuyi Iyasere; David Okai; Edwina Brown
Journal:  Clin Kidney J       Date:  2017-01-07

Review 2.  Cognition in chronic kidney disease: a systematic review and meta-analysis.

Authors:  Israel Berger; Sunny Wu; Philip Masson; Patrick J Kelly; Fiona A Duthie; William Whiteley; Daniel Parker; David Gillespie; Angela C Webster
Journal:  BMC Med       Date:  2016-12-14       Impact factor: 8.775

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.